Sarepta Therapeutics (SRPT) Stock Forecast, Price & News

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last twelve months. There are currently 1 hold rating and 15 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SRPT shares.
View SRPT analyst ratings or view top-rated stocks.

16 Wall Street research analysts have issued 1-year price objectives for Sarepta Therapeutics' shares. Their SRPT share price forecasts range from $122.00 to $218.00. On average, they anticipate the company's stock price to reach $168.76 in the next year. This suggests a possible upside of 31.9% from the stock's current price.
View analysts price targets for SRPT or view top-rated stocks among Wall Street analysts.

Sarepta Therapeutics' stock was trading at $129.58 on January 1st, 2023. Since then, SRPT shares have decreased by 1.3% and is now trading at $127.90.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023.
View our SRPT earnings forecast.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) issued its quarterly earnings data on Tuesday, May, 2nd. The biotechnology company reported ($0.97) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.46) by $0.49. The biotechnology company had revenue of $253.50 million for the quarter, compared to the consensus estimate of $241.47 million. Sarepta Therapeutics had a negative net margin of 114.30% and a negative trailing twelve-month return on equity of 128.64%. The company's quarterly revenue was up 20.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.20) EPS.

ETFs with the largest weight of Sarepta Therapeutics (NASDAQ:SRPT) stock in their portfolio include Direxion mRNA ETF (MSGR), Global X Genomics & Biotechnology ETF (GNOM), American Century Mid Cap Growth Impact (MID), iShares Neuroscience and Healthcare ETF (IBRN), First Trust NYSE Arca Biotechnology Index Fund (FBT), Principal Healthcare Innovators ETF (BTEC), Invesco Dynamic Biotechnology & Genome ETF (PBE) and AdvisorShares Dorsey Wright Alpha Equal Weight ETF (DWEQ).

15 employees have rated Sarepta Therapeutics Chief Executive Officer Douglas S. Ingram on Glassdoor.com. Douglas S. Ingram has an approval rating of 95% among the company's employees. This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV) and Walt Disney (DIS).

Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."

Sarepta Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.67%), Wellington Management Group LLP (3.15%), Bank of New York Mellon Corp (2.06%), State Street Corp (1.90%), Geode Capital Management LLC (1.35%) and Pictet Asset Management SA (1.30%). Insiders that own company stock include David T Howton, Douglas S Ingram, Hans Lennart Rudolf Wigzell, Joseph Bratica, Louise Rodino-Klapac, M Kathleen Behrens, Michael Andrew Chambers, Richard Barry and Stephen Mayo.
View institutional ownership trends.

Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SRPT stock can currently be purchased for approximately $127.90.

Sarepta Therapeutics (NASDAQ:SRPT) has a market capitalization of $11.91 billion and generates $933.01 million in revenue each year. The biotechnology company earns $-703,490,000.00 in net income (profit) each year or ($12.69) on an earnings per share basis.

The company employs 1,162 workers across the globe.

Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The official website for the company is www.sareptatherapeutics.com. The biotechnology company can be reached via phone at (617) 274-4000, via email at investors@sarepta.com, or via fax at 425-354-5038.